Immunotherapy targeting the autoimmune process in type 1 diabetes (T1D) can delay the
loss of β-cells but needs to have minimal adverse effects to be an adjunct to insulin in the …

A diagnosis of type 1 diabetes (T1D) and the subsequent requirement for exogenous insulin
treatment is associated with considerable acute and chronic morbidity and a substantial …

Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory
cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis …

Diabetes is a chronic illness that can become debilitating owing to its microvascular and
macrovascular complications. Its prevalence is increasing and so is its cost. Diabetes …

Type 1 diabetes (TID) is a chronic disease caused by autoimmune destruction of pancreatic
β-cells, that progresses in three stages: 1) stage 1: β-cell autoimmunity+ normoglycemia; 2) …

Introduction Despite therapeutic advances in the field of diabetes management since the
discovery of insulin 100 years ago, there are still unmet clinical needs for people with type 1 …

Type 1 diabetes results from autoimmune destruction of insulin-producing beta cells. There
is a genetic predisposition to the disease, with the greatest contribution conferred by alleles …

Diabetes affects around 500 million people worldwide. Diabetes is marked by raised blood
sugar levels owing to a relative or absolute lack of insulin, which is produced in pancreatic …

Methods: A cohort of 1,886 Sardinian patients, including 822 with CD, 1,064 with T1D, and
627 controls, underwent HLA class II ty**. Seventy-six out of 822 CD patients were also …